<i>Trigonella foenum-graecum</i> L. protects against renal function decline in a mouse model of type 2 diabetic nephropathy by modulating the PI3K-Akt-ERK signaling pathway.

ABSTRACT:

Objectives

Trigonella foenum-graecum L. (HLB) exhibits promising pharmacological properties for the treatment of type 2 diabetic nephropathy (DN). This study aims to enhance the understanding of HLB's pharmacodynamic effects and elucidate the mechanisms underlying its therapeutic potential in DN.

Methods

The pharmacodynamic effects of HLB were initially evaluated in a murine DN model through the oral administration of an aqueous extract of HLB. The primary bioactive constituents were subsequently identified using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). Network pharmacology analysis was integrated with these data to uncover potential molecular targets of HLB in DN. Key renal metabolites were profiled usi

SUBMITTER: Niu Y 

PROVIDER: S-EPMC11959092 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature